Codexis, Inc. (LON:0I0X)

Market Cap	78.78M -73.7%
Revenue (ttm)	39.38M -17.9%
Net Income	-47.58M
EPS	-0.56
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,939
Average Volume	16,637
Open	1.200
Previous Close	1.210
Day's Range	1.130 - 1.210
52-Week Range	1.130 - 5.200
Beta	2.47
RSI	33.20
Earnings Date	Feb 27, 2026

About Codexis

Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorp...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 188
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0I0X

Financial Performance

In 2024, Codexis's revenue was $59.35 million, a decrease of -15.39% compared to the previous year's $70.14 million. Losses were -$65.28 million, -14.38% less than in 2023.

Financial numbers in USD